Literature DB >> 24956171

Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.

Søren Dalsgaard1, Anette Primdal Kvist, James F Leckman, Helena Skyt Nielsen, Marianne Simonsen.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether stimulant users are at higher risk of a later cardiovascular event than are non-users, examining this association in both a national cohort and a population-based sample of children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD). We also aim to examine a possible dose-response relationship in such an association.
METHODS: We conducted a longitudinal, prospective cohort study of all children born in Denmark between 1990 and 1999. Within this cohort, children with ADHD were identified. Data from national health registers on psychiatric and somatic diagnoses, stimulant prescriptions, cardiovascular risk factors, pre- and perinatal and sociodemographic covariates in all children and their parents were merged, using the unique personal identification number. Hazard ratios (HR) for cardiovascular events were estimated using Cox regression, adjusted for other known risk factors.
RESULTS: In the total population (n=714,258 contributing a total of 6,767,982 person-years) use of stimulants increased the risk of a cardiovascular event; adjusted HR=1.83 (1.10-3.04). In children with ADHD (n=8300) stimulant treatment also increased the risk of a cardiovascular event (adjusted HR=2.20 [2.15-2.24]), with a complex time-dependent dose-response relationship.
CONCLUSIONS: This is the first nationwide cohort study of the cardiovascular safety of stimulants in children and adolescents, and it represents, to our knowledge, the longest prospective follow-up study. Cardiovascular events were rare but twice as likely in stimulant users as in non-users, both in the total national population and in children with ADHD. We found a complex, time- and dose-dependent interrelationship between cardiovascular adverse events and stimulant treatment in children and adolescents. Our results suggest a safety signal with an increased risk of cardiovascular disease associated with stimulant treatment in children and adolescents, even after adjusting for a number of potential confounders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24956171      PMCID: PMC4137345          DOI: 10.1089/cap.2014.0020

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  45 in total

1.  ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Authors:  Laurel A Habel; William O Cooper; Colin M Sox; K Arnold Chan; Bruce H Fireman; Patrick G Arbogast; T Craig Cheetham; Virginia P Quinn; Sascha Dublin; Denise M Boudreau; Susan E Andrade; Pamala A Pawloski; Marsha A Raebel; David H Smith; Ninah Achacoso; Connie Uratsu; Alan S Go; Steve Sidney; Mai N Nguyen-Huynh; Wayne A Ray; Joe V Selby
Journal:  JAMA       Date:  2011-12-12       Impact factor: 56.272

2.  The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.

Authors:  Hui-Chu Lang; Richard M Scheffler; Teh-Wei Hu
Journal:  Health Policy       Date:  2010-04-10       Impact factor: 2.980

3.  Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis.

Authors:  Paolo Fusar-Poli; Katya Rubia; Giorgio Rossi; Giuseppe Sartori; Umberto Balottin
Journal:  Am J Psychiatry       Date:  2012-03       Impact factor: 18.112

4.  Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.

Authors:  S Dresel; J Krause; K H Krause; C LaFougere; K Brinkbäumer; H F Kung; K Hahn; K Tatsch
Journal:  Eur J Nucl Med       Date:  2000-10

5.  Coffee consumption during pregnancy and the risk of hyperkinetic disorder and ADHD: a prospective cohort study.

Authors:  Karen Markussen Linnet; Kirsten Wisborg; Niels Jørgen Secher; Per Hove Thomsen; Carsten Obel; Søren Dalsgaard; Tine Brink Henriksen
Journal:  Acta Paediatr       Date:  2008-09-01       Impact factor: 2.299

Review 6.  Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence.

Authors:  Karen Markussen Linnet; Søren Dalsgaard; Carsten Obel; Kirsten Wisborg; Tine Brink Henriksen; Alina Rodriguez; Arto Kotimaa; Irma Moilanen; Per Hove Thomsen; Jørn Olsen; Marjo-Riitta Jarvelin
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

7.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Authors:  Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

8.  Cardiac repolarization and striatal dopamine transporter function are interrelated.

Authors:  Esa Kauppila; Esko Vanninen; Tom Kuusela; Salla Kaurijoki; Leila Karhunen; Kirsi H Pietiläinen; Aila Rissanen; Jaakko Kaprio; Jari Tiihonen; Jyrki Kuikka
Journal:  Nucl Med Commun       Date:  2009-09       Impact factor: 1.690

Review 9.  Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Authors:  Arthur N Westover; Ethan A Halm
Journal:  BMC Cardiovasc Disord       Date:  2012-06-09       Impact factor: 2.298

10.  European guidelines on managing adverse effects of medication for ADHD.

Authors:  J Graham; T Banaschewski; J Buitelaar; D Coghill; M Danckaerts; R W Dittmann; M Döpfner; R Hamilton; C Hollis; M Holtmann; M Hulpke-Wette; M Lecendreux; E Rosenthal; A Rothenberger; P Santosh; J Sergeant; E Simonoff; E Sonuga-Barke; I C K Wong; A Zuddas; H-C Steinhausen; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-11-03       Impact factor: 4.785

View more
  26 in total

1.  Stimulants Use in Attention Deficit Hyperactivity Disorder (ADHD) Kids - Triumph or Tribulation?

Authors:  Ahmed Naguy
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2016-11-01

2.  Impact of Stimulant Medication Use on Heart Rate and Systolic Blood Pressure During Submaximal Exercise Treadmill Testing in Adolescents.

Authors:  Arthur N Westover; Paul A Nakonezny; Bryon Adinoff; Edson Sherwood Brown; Ethan A Halm
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-09-14       Impact factor: 2.576

3.  Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.

Authors:  Gregory R Sayer; James J McGough; Jennifer Levitt; Jennifer Cowen; Alexandra Sturm; Edward Castelo; James T McCracken
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-08-02       Impact factor: 2.576

Review 4.  Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners.

Authors:  Kelly A Brown; Sharmeen Samuel; Dilip R Patel
Journal:  Transl Pediatr       Date:  2018-01

5.  Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.

Authors:  Pernille Warrer; Per Hove Thomsen; Søren Dalsgaard; Ebba Holme Hansen; Lise Aagaard; Helle Wallach Kildemoes; Henrik Berg Rasmussen
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-02-18       Impact factor: 2.576

Review 6.  Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.

Authors:  Jose Martinez-Raga; Amparo Ferreros; Carlos Knecht; Raquel de Alvaro; Eloisa Carabal
Journal:  Ther Adv Drug Saf       Date:  2016-11-29

Review 7.  Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Kim Boesen; Asger Sand Paludan-Müller; Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2022-02-24

Review 8.  A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder.

Authors:  Leslie Briars; Timothy Todd
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun

9.  Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.

Authors:  Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

Review 10.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.